Current MEG Announcements
MEG Annual Dues Elimination / Optional Donations for the MEG Scholar-in-Training Awards (SITAs) Requested
The epidemiology community is collaborative by its very nature. To ensure maximal participation by all interested, the MEG and AACR leadership have removed MEG dues beginning with the 2020 dues renewal cycle beginning in September 2019. The majority of these dues supported the three MEG Scholar-in-Training Awards. Please consider a donation to the MEG Scholar-in-Training fund when renewing or initiating your membership. For assistance, contact email@example.com. Thank you for your continued support of early-career scholars!
Plan to attend the MEG events at the AACR Annual Meeting 2020
Be sure to watch for the information coming shortly regarding the AACR Annual Meeting 2020 and how you can register and reserve lodging in advance! We especially look forward to seeing you at the MEG events being planned to take place there.
Remember, too, that the "Call for Abstracts" opens Tuesday, Sept. 24, 2019!
From the Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
The Epidemiology and Genomics Research Program in NCI’s Division of Cancer Control and Population Sciences invites AACR-MEG members to register for upcoming webinars.To learn more about the EGRP's webinar series, visit the SeqSPACE Upcoming Topics and Speakers webpage. Upcoming presentations include:
Sequencing in the CARRIERS Consortium and Other Lessons Learned from Cancer Predisposition Gene Sequencing Studies
Sept. 17, 2019, 3 to 4:30 p.m. ET
Fergus J. Couch, PhD
Dr. Fergus Couch is a Zbigniew and Anna M. Scheller professor of medical research and chair of the Division of Experimental Pathology and Laboratory Medicine at the Mayo Clinic in Rochester, Minnesota. He studies how genetic alterations influence the development of both breast and pancreatic cancer. The long-term goals of his research program are to develop methods that predict an individual's risk of developing breast cancer and facilitate cancer prevention efforts, as well as develop tests that improve selection of treatment for individuals with breast and pancreatic cancer. In this webinar, Dr. Couch will be presenting on sequencing in the CARRIERS consortium and other lessons learned from cancer predisposition gene sequencing studies.Register for this webinar
Practical Considerations for Genomic Sequencing Studies in a Low Resource Setting
Oct. 22, 2019, 3 to 4:30 p.m. ET
Timothy Rebbeck, PhD
Dr. Timothy Rebbeck is a is a Vincent L. Gregory Jr. professor of cancer prevention and epidemiology at the Harvard T.H. Chan School of Public Health as well as a professor of medical oncology at the Dana-Farber Cancer Institute. He leads molecular epidemiology studies of cancer etiology, outcomes, health disparities, and global health. His work has led to an understanding of the genetic and environmental causes of breast, prostate, skin, endometrial and ovarian cancers. He founded and led international cancer consortia that study risk and outcomes of 1) cancer in BRCA1/BRCA2 mutation carriers, and 2) prostate cancer in men of African descent in North America, the Caribbean, and Africa. Dr. Rebbeck will be presenting on practical considerations for genomic sequencing studies in a low resource setting.Register for this webinar
Lessons Learned Sequencing Precancerous Lesions
Nov. 12, 2019, 3 to 4:30 p.m. ET
Avrum Spira, MD, MSc
Dr. Avrum Spira is professor of medicine, pathology and laboratory medicine, and bioinformatics and Alexander Graham Bell professor of healthcare entrepreneurship at the Boston University School of Medicine (BUSM). He is also chief of the Division of Computational Biomedicine at the BUSM. In addition, he is the director of the Translational Bioinformatics Program at the Clinical and Translational Science Institute and director of the JNJ Innovation Lung Cancer Center at Boston University. His laboratory research interests focus on applying genomic and bioinformatics tools to the translational study of lung cancer and chronic obstructive lung disease (COPD), with the ultimate objective of developing novel diagnostics and therapeutics that can directly impact clinical care. In this webinar, Dr. Spira will be presenting on lessons learned sequencing precancerous lesions.Register for this webinar
Strategies for Sequencing the Microbiome
Dec. 3, 2019, 3 to 4:30 p.m. ET
Andrew T. Chan, MD, MPH
Dr. Andrew Chan is a professor of medicine at Harvard Medical School. He is also vice chair of education and gastroenterology as well as chief of the Clinical and Translational Epidemiology Unit at Massachusetts General Hospital. Dr. Chan’s overall mission is to advance epidemiologic investigation for the translation of discoveries into effective clinical interventions. He currently focuses on chronic digestive diseases, including gastrointestinal cancer (colorectal, esophageal, pancreatic), inflammatory bowel disease, diverticulitis, and gastrointestinal bleeding. He utilizes molecular approaches encompassing genetic, metabolomic, proteomic, and biochemical platforms applied to populations ranging from large cohort studies to small biomarker-driven clinical trials. He also investigates the oral and gut microbiome as a determinant and mediator of chronic disease. Dr. Chan will be presenting on strategies for sequencing the microbiome.Register for this webinar
Research Identifying Germline Predisposition Variants in Sequencing Studies
Feb. 4, 2020, 3 to 4:30 p.m. ET
Fernanda Martins Rodrigues, MSc
Ms. Fernanda Martins Rodrigues is a PhD student in molecular genetics at Washington University in Saint Louis working with Dr. Li Ding at the Ding Lab External Web Site Policy. The goal of her research is to use computational tools to better understand cancer genetics. In this webinar, Ms. Martins Rodrigues will be presenting on research identifying germline predisposition variants in sequencing studies.Register for this webinar
Be Sure to See the AACR Blog: Cancer Research Catalyst!
See current scientific research updates in the AACR's blog Cancer Research Catalyst, and learn how you can submit content!
Request for Proposals for Genome-wide Investigation of Late-effects Using the Childhood Cancer Survivor Study (CCSS) Cohort
The Childhood Cancer Survivor Study (CCSS) is an NCI-funded resource for the study of long-term survivors of cancer diagnosed during childhood and adolescence. Learn the details regarding the cohort.
Members of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute and CCSS investigators collaborated to conduct a genome-wide association study, initially intended to study the role of genetic susceptibility in the development of subsequent neoplasms as well as first primary childhood cancers using samples from the CCSS Biorepository. Genotyping was conducted for 5739 childhood cancer survivors diagnosed 1970-1986 (5324 are of European ancestry) using the Illumina HumanOmni5Exome microarray, with over 4.1 million loci passing quality control thresholds (based on locus and sample missing rates, sample heterozygosity, and sex discrepancies).
The CCSS leadership is now broadening the scope of this initiative to study the role of genetic susceptibility in the development of non-malignant, treatment-related outcomes in cancer survivors. Accordingly, CCSS is announcing a request for proposals to collaborate with CCSS and NCI investigators in the use of existing genome-wide association study (GWAS) data and corresponding outcomes-related data to address innovative research questions relating to potential genetic contributions to risk for non-malignant treatment-related outcomes. Requests will be accepted on an ongoing basis and will be reviewed three times per year, in February, June, and October (cut-off for receipt of applications February 1, June 1, October 1).
Learn more details regarding the application process as well as the application for data access.
MEG Members Receive an Additional 5 Percent Discount on CEBP Accepted Manuscripts
MEG members receive a special 5 percent discount for publication fees only (not AuthorChoice) for articles accepted in Cancer Epidemiology, Biomarkers & Prevention (CEBP). This is in addition to the 5 percent discount given to all AACR members. Thus, MEG members receive a total discount of 10 percent. Just use the code "MEGAO2019" when receiving notification from the CEBP staff about author billing. See the information for authors for CEBP submissions. We look forward to receiving your submission.
CancerCareers Discounts Available
Be sure to check out www.cancercareers.org for career opportunities. MEG members now receive a 15 percent discount for all employment postings. Use the code MEGAD when submitting your advertisement to receive this special rate. You can also sign-up for job alerts and refine a job search by a specific research area, i.e. epidemiology; prevention. Look on the right side of the website for these options.
To Submit an Announcement for Consideration, Please Note:
Employment opportunities should be sent to cancercareers.org for posting consideration on that website. Please refer all questions regarding employment posting to
Postings of a non-employment nature may still be sent to firstname.lastname@example.org for review and possible future posting on the MEG Announcements.
Best regards from everyone at the AACR, and sincere appreciation for your